Medpace Holdings Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Consumer Staples Select Sector SPDR Fund trades at $84.8. Which is the better fit depends on your goals.
| MEDP | XLP | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | — |
52-Week High | $620.59 | $90.00 |
52-Week Low | $308.88 | $75.61 |
Enterprise Value | $14.55B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
XLP trades at $84.86, down 0.39% on the day, with a bullish technical signal supported by moving averages. The ETF maintains a 2.6% dividend yield and shows strength in defensive positioning amid market volatility. Analyst consensus is unanimously positive with 2 buy ratings and no hold or sell recommendations.
The consumer staples ETF offers defensive exposure during economic uncertainty, with technical indicators supporting near-term upside potential. Key risks include sector concentration and competition from broader alternatives. Current levels near pivot point resistance at $86 represent the immediate technical challenge.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →